-
21.发明申请METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE 审中-公开使用遗传变异体进行诊断和预防炎症性皮肤疾病的方法公开(公告)号：US20100240043A1
公开(公告)日：2010-09-23
申请号：US12675718
申请日：2008-10-20
申请人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Dermot P. McGovern , Ling Mei , Xiaowen Su
发明人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Dermot P. McGovern , Ling Mei , Xiaowen Su
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.
摘要翻译： 本发明涉及诊断易感性肠炎和炎症性肠病亚型的易感性的方法。 在一个实施方案中，本发明提供了通过确定在DR3基因座，GATA3基因座，SIN（EFS）基因座，BTLA基因座，LIGHT基因座和MAGE基因座处存在一种或多种风险变体来诊断易感性肠炎易感性的方法。
-
公开(公告)号：US20140017711A1
公开(公告)日：2014-01-16
申请号：US14007381
申请日：2012-03-26
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/156 , G01N33/564 , G01N2800/065 , G01N2800/54 , G01N2800/56
摘要： The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype.
摘要翻译： 本发明涉及通过确定存在至少一种风险遗传变异体和/或至少一种风险血清学标记物来预测个体中炎症性肠病（IBD）的方法。 在一个实施方案中，风险血清学标记ANCA的存在表示侵略性形式的溃疡性结肠炎。 在另一个实施方案中，本发明涉及在个体中诊断克罗恩病亚型的方法，其中存在风险变体和血清学标志物I2，OmpC和/或Cbir1表示克罗恩氏病亚型。
-
23.发明申请公开(公告)号：US20130136720A1
公开(公告)日：2013-05-30
申请号：US13521622
申请日：2011-01-14
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus.
摘要翻译： 本发明涉及克罗恩病的预后，诊断和治疗。 本发明还提供了基于在FUT2遗传基因座处存在一种或多种遗传危险因素的预后，诊断和治疗。
-
24.发明申请CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开CBIR1抗原反应诊断和治疗高血糖病的特征公开(公告)号：US20130058953A1
公开(公告)日：2013-03-07
申请号：US13410881
申请日：2012-03-02
IPC分类号： C12Q1/68 , C40B30/04 , G01N33/566 , A61K39/40 , A61P1/00
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/156 , C12Q2600/172
摘要： This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.
摘要翻译： 本发明通过确定遗传变异体的存在或不存在来提供诊断或预测克罗恩病敏感性的方法。 在一个实施方案中，本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。 在另一个实施方案中，本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。 在另一个实施方案中，本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。
-
公开(公告)号：US20120208900A1
公开(公告)日：2012-08-16
申请号：US13372359
申请日：2012-02-13
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
摘要翻译： 本发明涉及通过确定一种或多种风险变体的存在或不存在来预测个体中严重形式的克罗恩病易感性的方法。 在一个实施方案中，风险变体包括遗传风险变体和临床危险因素的组合。 在另一个实施方案中，遗传风险变体位于IL12B遗传基因座。 在另一个实施方案中，克罗恩病的严重形式的特征在于快速进展到需要手术治疗的病症。
-
公开(公告)号：US20120073585A1
公开(公告)日：2012-03-29
申请号：US13263707
申请日：2010-04-08
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.
摘要翻译： 本发明涉及预测，诊断和治疗克罗恩病的攻击性形式，其特征在于从诊断时快速进展为并发症和/或手术。 在一个实施方案中，预后，诊断和治疗是基于一种或多种遗传危险因素的存在。
-
公开(公告)号：US20100144903A1
公开(公告)日：2010-06-10
申请号：US12598794
申请日：2008-05-02
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus.
摘要翻译： 在一个实施方案中，本发明通过确定IL23R，IL17A，IL17RA和/或IL12RB1基因座中风险单倍体的存在或不存在来提供诊断和/或预测克罗恩病易感性的方法。 在另一个实施方案中，本发明提供了通过确定在IL12RB2基因座处存在或不存在风险单倍型来诊断和/或预测个体中克罗恩病易感性的方法。
-
公开(公告)号：US09902996B2
公开(公告)日：2018-02-27
申请号：US13372359
申请日：2012-02-13
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
-
29.发明授权Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy 有权预测需要结肠切除术的医疗屈光性溃疡性结肠炎（MR-UC）的方法公开(公告)号：US09580752B2
公开(公告)日：2017-02-28
申请号：US13140874
申请日：2009-12-24
申请人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
发明人： Jerome I. Rotter , Kent D. Taylor , Stephan R. Targan , Talin Haritunians , Dermot P. McGovern , Xiuqing Guo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N2800/067
摘要： Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
摘要翻译： 公开了预测患者中医学难治性溃疡性结肠炎（MR-UC）的发展的方法。在一个实施方案中，公开了通过确定一种或多种风险变异体的存在或不存在来预测个体中溃疡性结肠炎的方法，其中 一种或多种风险变体的存在表示严重和/或侵略性形式的溃疡性结肠炎。 在另一个实施方案中，严重形式的溃疡性结肠炎指示MR-UC。
-
30.发明申请METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE 审中-公开使用单核苷酸多态性在TL1A基因中预测或诊断炎症性皮肤病的方法公开(公告)号：US20100190162A1
公开(公告)日：2010-07-29
申请号：US12528055
申请日：2008-02-26
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C07K16/2875 , C07K2317/76 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6893 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
摘要翻译： 本发明提供通过确定TL1A基因中遗传变异体的存在或不存在来诊断或预测对炎症性肠病易感性的方法。 在一个实施方案中，通过测定Fc-γ-R活化后TL1A产生的存在或不存在来实施本发明的方法。 在另一个实施方案中，本发明提供通过抑制TL1A治疗炎性肠病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.044 秒)
